We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+9.27%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+879.75%
AUM
$49B
AUM Growth
+$3.11B
(+6.8%)
Cap. Flow
+$228M
Cap. Flow
% of AUM
0.47%
Top 10 Holdings %
Top 10 Hldgs %
21.37%
Holding
1,104
New
303
Increased
294
Reduced
324
Closed
153
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$282M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$205M |
| 3 |
ConocoPhillips
COP
|
+$203M |
| 4 |
Fortive
FTV
|
+$200M |
| 5 |
Merck
MRK
|
+$178M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$665M |
| 2 |
ExxonMobil
XOM
|
+$332M |
| 3 |
Burlington
BURL
|
+$242M |
| 4 |
National Vision
EYE
|
+$186M |
| 5 |
CXO
CONCHO RESOURCES INC.
CXO
|
+$175M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.67% |
| 2 | Healthcare | 17.99% |
| 3 | Financials | 14.03% |
| 4 | Consumer Discretionary | 11.97% |
| 5 | Communication Services | 8.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
WCC
301
WESCO International
WCC
$18.1B
| $34.4M | 0.07% |
+397,276
| New | +$33.4M |
|
302
Trimble
TRMB
$13.6B
| $34.3M | 0.07% |
+441,458
| New | +$31.9M |
|
303
Paychex
PAYX
$42.7B
| $33.9M | 0.07% |
345,646
-7,200
| -2% | -$663K |
|
304
Cabaletta Bio
CABA
$450M
| $33.8M | 0.07% |
3,041,645
-139,160
| -4% | -$1.7M |
|
305
SBA Communications
SBAC
$19.4B
| $33.7M | 0.07% |
121,500
+97,700
| +411% | +$25.9M |
|
|
BOAC
306
DELISTED
Bluescape Opportunities Acquisition Corp.
BOAC
| $33.5M | 0.07% |
3,363,526
+2,069,776
| +160% | +$22M |
|
307
Timken Company
TKR
$8.92B
| $33.2M | 0.07% |
409,120
+331,177
| +425% | +$26.4M |
|
308
Vinci Compass Investments Ltd
VINP
$650M
| $33.2M | 0.07% |
+2,523,262
| New | +$40.9M |
|
309
Welltower
WELL
$170B
| $33.1M | 0.07% |
462,306
+2,200
| +0.5% | +$148K |
|
310
D.R. Horton
DHI
$40.8B
| $32.7M | 0.07% |
366,775
-2,500
| -0.7% | -$196K |
|
|
AAC
311
DELISTED
Ares Acquisition Corporation
AAC
| $32.7M | 0.07% |
+3,300,000
| New | +$32.6M |
|
|
ANSS
312
DELISTED
Ansys
ANSS
| $32.6M | 0.07% |
96,100
+3,200
| +3% | +$1.14M |
|
313
C4 Therapeutics
CCCC
$402M
| $32.6M | 0.07% |
880,498
-10,000
| -1% | -$398K |
|
314
Williams Companies
WMB
$87.8B
| $32M | 0.07% |
1,349,399
+74,700
| +6% | +$1.7M |
|
|
BNY
315
Bank of New York Mellon
BNY
$108B
| $31.9M | 0.07% |
675,016
-254,134
| -27% | -$11.2M |
|
316
XP
XP
$8.62B
| $31.9M | 0.07% |
845,977
-360,228
| -30% | -$15.4M |
|
317
MeiraGTx Holdings
MGTX
$1.18B
| $31.7M | 0.06% |
2,200,000
+250,000
| +13% | +$3.91M |
|
|
PRPC.U
318
DELISTED
CC Neuberger Principal Holdings III Units, each consisting of one Class A ordinary share, and one-fifth of one redeemable warrant
PRPC.U
| $31.5M | 0.06% |
+3,150,000
| New | +$32.5M |
|
319
DexCom
DXCM
$31.3B
| $31.2M | 0.06% |
347,100
-159,400
| -31% | -$15M |
|
320
ProQR Therapeutics
PRQR
$268M
| $31M | 0.06% |
4,694,465
+144,403
| +3% | +$738K |
|
321
Lennar Class A
LEN
$20.4B
| $30.9M | 0.06% |
315,599
-930
| -0.3% | -$78.2K |
|
322
F5
FFIV
$23.5B
| $30.9M | 0.06% |
148,200
-61,300
| -29% | -$12.1M |
|
323
Skyworks Solutions
SWKS
$10.1B
| $30.7M | 0.06% |
167,450
+15,300
| +10% | +$2.66M |
|
|
TCF
324
DELISTED
TCF Financial Corporation Common Stock
TCF
| $30.5M | 0.06% |
656,058
-370,158
| -36% | -$16.4M |
|
325
Gentex
GNTX
$4.96B
| $30.5M | 0.06% |
853,752
-171,456
| -17% | -$6.09M |
|
Similar funds
Adage Capital Partners's Q1 2021 Portfolio in Review
As of Q1 2021, Adage Capital Partners held 1,104 positions worth $49B, up 6.8% from $45.9B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Adage Capital Partners's Q1 2021 filing shows 303 new, 294 increased, 324 reduced and 153 closed positions. Its largest new stake was GW Pharmaceuticals Plc American Depositary Shares: 1,500,000 shares worth $325M. The largest sale was Royalty Pharma, an estimated $665M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 21% a quarter earlier, followed by Healthcare and Financials.
- Adage Capital Partners's largest Q1 2021 buy was GW Pharmaceuticals Plc American Depositary Shares: 1,500,000 shares worth $325M.
- Adage Capital Partners added most to Alexion Pharmaceuticals in Q1 2021, an estimated $205M increase.
- Adage Capital Partners's biggest Q1 2021 reduction was Royalty Pharma, cutting an estimated $665M.
- Adage Capital Partners fully exited CONCHO RESOURCES INC. in Q1 2021, selling an estimated $175M.
- Adage Capital Partners's ten largest holdings make up 21% of its $49B portfolio in Q1 2021.
- Adage Capital Partners opened 303 new positions and closed 153 in Q1 2021.
- Adage Capital Partners's portfolio value rose 6.8% quarter-over-quarter to $49B.
Based on Adage Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.